Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
AssigneeSynovex Corporation
InventorJames G. McArthur
Life of this patent
Estimating the term…
Abstract
The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumatoid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist.
Claims33
1-3. (canceled)
An isolated antibody that specifically binds an EC1 domain of a mammalian Cadherin-11 protein, wherein the antibody inhibits aggregation of cells that express said mammalian Cadherin-11 protein.
(canceled)
10-45. (canceled)
49-52. (canceled)
(canceled)
(canceled)
(canceled)
An antibody produced by hybridoma H1M1 (ATCC Patent Deposit Designation PTA-9699).
An antibody produced by hybridoma H14 (ATCC Patent Deposit Designation PTA-9701).
(canceled)
(canceled)
(canceled)
(canceled)
An isolated antibody that specifically binds an EC1 domain of a mammalian Cadherin-11 protein, comprising a first antibody variable region having:
- a) a CDR1 consisting of SEQ ID NO:52;
- b) a CDR2 consisting of SEQ ID NO:53;
- and
- c) a CDR3 consisting of SEQ ID NO:54;
- wherein the antibody inhibits aggregation of cells that express said mammalian Cadherin-11 protein.
An isolated antibody that specifically binds an EC1 domain of a mammalian Cadherin-11 protein, comprising an antibody variable region comprising:
- a) a CDR1 consisting of SEQ ID NO:57;
- b) a CDR2 consisting of SEQ ID NO:58;
- and
- c) a CDR3 consisting of SEQ ID NO:59;
- wherein the antibody inhibits aggregation of cells that express said mammalian Cadherin-11 protein.
Dependencies are inferred from the claim text.